CN105012972A - 放射性标记方法 - Google Patents

放射性标记方法 Download PDF

Info

Publication number
CN105012972A
CN105012972A CN201510494983.3A CN201510494983A CN105012972A CN 105012972 A CN105012972 A CN 105012972A CN 201510494983 A CN201510494983 A CN 201510494983A CN 105012972 A CN105012972 A CN 105012972A
Authority
CN
China
Prior art keywords
formula
compound
carrier
peptide
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510494983.3A
Other languages
English (en)
Chinese (zh)
Inventor
E.阿斯塔
M.E.格拉泽尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Amersham Health AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Health AS filed Critical Amersham Health AS
Publication of CN105012972A publication Critical patent/CN105012972A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201510494983.3A 2004-12-22 2005-12-09 放射性标记方法 Pending CN105012972A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0428012.9A GB0428012D0 (en) 2004-12-22 2004-12-22 Radiolabelling methods
GB0428012.9 2004-12-22
CNA2005800441130A CN101084020A (zh) 2004-12-22 2005-12-09 放射性标记方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800441130A Division CN101084020A (zh) 2004-12-22 2005-12-09 放射性标记方法

Publications (1)

Publication Number Publication Date
CN105012972A true CN105012972A (zh) 2015-11-04

Family

ID=34112991

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510494983.3A Pending CN105012972A (zh) 2004-12-22 2005-12-09 放射性标记方法
CNA2005800441130A Pending CN101084020A (zh) 2004-12-22 2005-12-09 放射性标记方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800441130A Pending CN101084020A (zh) 2004-12-22 2005-12-09 放射性标记方法

Country Status (13)

Country Link
US (2) US7972588B2 (https=)
EP (4) EP1830890A2 (https=)
JP (2) JP5743372B2 (https=)
KR (1) KR101314460B1 (https=)
CN (2) CN105012972A (https=)
AU (1) AU2005317903C1 (https=)
BR (1) BRPI0519317A2 (https=)
CA (2) CA2817636A1 (https=)
GB (1) GB0428012D0 (https=)
MX (1) MX2007007560A (https=)
NO (1) NO341638B1 (https=)
RU (1) RU2419627C2 (https=)
WO (1) WO2006067376A2 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071718B2 (en) 2004-12-22 2011-12-06 General Electric Company Selective radiolabeling of biomolecules
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
WO2007148074A1 (en) * 2006-06-21 2007-12-27 Hammersmith Imanet Limited Chemical methods and apparatus
JP2009541288A (ja) 2006-06-21 2009-11-26 ハマースミス・イメイネット・リミテッド 放射性標識方法
EP2056886A2 (en) * 2006-08-28 2009-05-13 GE Healthcare Limited 68ga-labeled peptide-based radiopharmaceuticals
WO2008025886A1 (en) * 2006-09-01 2008-03-06 Wallac Oy Metal chelates and chelating agents containing triazolyl subunits
EP2155259A2 (en) * 2007-05-10 2010-02-24 The Trustees of Columbia University in the City of New York Methods for diagnosing diseases and evaluating treatments therefor using pet
KR101563758B1 (ko) * 2007-12-20 2015-10-27 제너럴 일렉트릭 캄파니 생체분자의 선택적 방사선표지
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
KR20110066927A (ko) 2008-09-05 2011-06-17 임페리얼 이노베이션스 리미티드 생체 내 영상화제로서 사용하기 위한 이사틴 유도체
CA2736861C (en) * 2008-10-10 2017-11-14 Roger Schibli 18f-labelled folates as pet radiotracers
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
EP2210882A1 (en) * 2009-01-16 2010-07-28 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Synthesis of new protected azahistidine, their processes and their use in synthesises
EP2400992B1 (en) * 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
US8722014B2 (en) * 2009-05-01 2014-05-13 Washington University 1 H-[1, 2, 3] triazole substituted amino acids and uses thereof
GB0914543D0 (en) * 2009-08-20 2009-09-30 Ge Healthcare Ltd Radioiodination method
WO2011058002A1 (en) * 2009-11-11 2011-05-19 Neurosearch A/S Labelled pyrrolyl-oxadiazolyl-diazabicyclononane derivatives and their use in diagnostic methods
GB0921573D0 (en) * 2009-12-10 2010-01-27 Ge Healthcare Ltd Iodine radiolabelling method
GB0922304D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Ltd Radioiodinated compounds
WO2011079245A1 (en) * 2009-12-23 2011-06-30 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
WO2011130530A1 (en) * 2010-04-14 2011-10-20 The Mclean Hospital Corporation 2-alkoxy-11-hydroxyaporphine derivatives and uses thereof
WO2011153250A2 (en) 2010-06-01 2011-12-08 Advanced Proteome Therapeutics Inc. Crosslinking of proteins and other entities via conjugates of alpha-haloacetophenones, benzyl halides, quinones, and their derivatives
US10434197B2 (en) * 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
GB201014023D0 (en) * 2010-08-20 2010-10-06 Ucl Business Plc Process for producing bioconjugates and products thereof
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
GB201019824D0 (en) 2010-11-23 2011-01-05 Ge Healthcare Ltd Radioiodination method
GB201021369D0 (en) 2010-12-16 2011-01-26 Ge Healthcare Ltd Radioiodinated fatty acids
GB201021517D0 (en) 2010-12-20 2011-02-02 Ge Healthcare Ltd Radioiodinated guanidines
RU2013128360A (ru) 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
NZ612161A (en) 2010-12-22 2015-04-24 Gen Electric Radiolabled her2 binding peptides
AU2012223364A1 (en) 2011-03-01 2013-09-19 Ge Healthcare Limited Radiolabelled Octreotate analogues as PET tracers
US20120251448A1 (en) * 2011-03-03 2012-10-04 Hefti Franz F Compounds for Use in the Detection of Neurodegenerative Diseases
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
WO2013048832A1 (en) 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
WO2013082508A1 (en) * 2011-12-02 2013-06-06 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
GB201121911D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Radiofluorination method
WO2013113680A1 (en) * 2012-02-03 2013-08-08 Aarhus Universitet Radiolabeled bile acids and bile acid derivatives
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
US20140065070A1 (en) * 2012-08-28 2014-03-06 Mcmaster University Methods of preparing triazole-containing radioiodinated compounds
WO2014065413A1 (ja) * 2012-10-26 2014-05-01 日本たばこ産業株式会社 トリアゾール・イソオキサゾール化合物およびその医薬用途
US20150023877A1 (en) * 2013-07-18 2015-01-22 The Board Of Trustees Of The Leland Stanford Junior University Methods of parkinsons disease diagnosis and monitoring treatment
CA2935857C (en) * 2014-01-05 2020-12-15 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
US20160022846A1 (en) * 2014-07-22 2016-01-28 Ge Healthcare Limited Iodine radiolabelling method
SMT202000633T1 (it) * 2015-06-19 2021-01-05 Eisai R&D Man Co Ltd Immunoglobuline coniugate a cys80
US10434195B2 (en) * 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
EP3826673A4 (en) * 2018-07-26 2022-03-09 Tayu Huaxia Biotech Medical Group Co., Ltd. COMPOSITIONS AND METHODS FOR IMAGING

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
AU4589701A (en) 2000-03-24 2001-10-08 Cocensys Inc Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof
US6350360B1 (en) 2000-04-07 2002-02-26 Sandia Coroporation Method of fabricating a 3-dimensional tool master
CA2405469C (en) * 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
JP4638225B2 (ja) 2002-05-30 2011-02-23 ザ スクリプス リサーチ インスティテュート 銅を触媒とするアジドとアセチレンのライゲーション
WO2004055160A2 (en) * 2002-12-13 2004-07-01 The Trustees Of Columbia University In The City Of New York Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
JP5642916B2 (ja) * 2003-04-17 2014-12-17 ザ スクリプス リサーチ インスティテュート 真核遺伝コードの拡張
EP2410331B1 (en) * 2003-06-18 2015-09-23 The Scripps Research Institute Aminoacyl-tRNA synthetase for aminoacylation tRNA with unnatural amino acids
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
EP1809339A2 (en) * 2004-10-07 2007-07-25 Koninklijke Philips Electronics N.V. Compounds, kits and methods for use in medical imaging
GB0428012D0 (en) * 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods

Also Published As

Publication number Publication date
KR101314460B1 (ko) 2013-10-10
GB0428012D0 (en) 2005-01-26
US8679455B2 (en) 2014-03-25
AU2005317903C1 (en) 2012-05-10
JP2012254998A (ja) 2012-12-27
JP2008528445A (ja) 2008-07-31
US20110236311A1 (en) 2011-09-29
NO20073157L (no) 2007-06-20
CA2589136C (en) 2015-10-06
CN101084020A (zh) 2007-12-05
RU2007122804A (ru) 2009-01-27
CA2589136A1 (en) 2006-06-29
AU2005317903A1 (en) 2006-06-29
MX2007007560A (es) 2007-11-21
EP2266629B1 (en) 2015-12-09
AU2005317903B2 (en) 2011-12-01
BRPI0519317A2 (pt) 2009-01-13
EP2266629A1 (en) 2010-12-29
CA2817636A1 (en) 2006-06-29
RU2419627C2 (ru) 2011-05-27
EP2258403A1 (en) 2010-12-08
EP2275145A1 (en) 2011-01-19
JP5743372B2 (ja) 2015-07-01
WO2006067376A3 (en) 2007-07-26
WO2006067376A2 (en) 2006-06-29
US20090311177A1 (en) 2009-12-17
US7972588B2 (en) 2011-07-05
KR20070091626A (ko) 2007-09-11
AU2005317903B8 (en) 2012-01-19
EP1830890A2 (en) 2007-09-12
NO341638B1 (no) 2017-12-18

Similar Documents

Publication Publication Date Title
JP5743372B2 (ja) 放射性標識法
US8409547B2 (en) Radiolabelling methods
JP5318874B2 (ja) 放射性フッ素化方法
JP2009541286A (ja) 化学的方法及び装置
US8216548B2 (en) Radiofluorination methods
US20080213174A1 (en) Radiolabelled Insulin
AU2013204443A1 (en) Radiolabelling methods
HK1136587A (en) Chemical methods and apparatus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20170126

Address after: Buckinghamshire

Applicant after: GE HEALTHCARE Ltd.

Address before: London, England

Applicant before: HAMMERSMITH IMANET LTD.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151104